Can Bristol Myers Squibb and Pfizer protect Eliquis growth as drug pricing pressure rises?
Eliquis faces pricing pressure, but Bristol Myers Squibb and Pfizer are moving first. Direct access may become pharma’s new defence.
Pharma & Biotech
Pharma & Biotech
What LEVI-04 data suggest about the future of disease-modifying osteoarthritis therapies
LEVI-04 Phase II data from Levicept Ltd. signal a shift in osteoarthritis treatment. Discover what this means for disease-modifying therapies.
Pharma & Biotech
How Novartis Pharma AG is targeting the last untreated segment in malaria care
Discover how Novartis Pharma AG is targeting neonatal malaria with Coartem Baby and what WHO prequalification means for global access.
Pharma & Biotech
Why Novartis Pharma AG’s Itvisma could redefine treatment pathways for older SMA patients
Novartis Pharma AG’s Itvisma gains CHMP support in SMA. Find out how gene therapy could reshape treatment for older patients in Europe.
Pharma & Biotech
How Amphista Therapeutics is positioning non-cereblon degraders for next-generation oncology pipelines
Discover how Amphista Therapeutics’ SMARCA2 and TEAD degrader data could redefine targeted cancer therapies. Read the full analysis now.
Pharma & Biotech
Sanofi’s Tzield gains pediatric approval but can early intervention truly change T1D outcomes
FDA expands Tzield use to young children with type 1 diabetes. Discover what this means for early intervention and long-term outcomes.
Pharma & Biotech
Cipla just cracked a $1.5bn U.S. inhaler market. Here’s why it matters
Find out how Cipla’s U.S. FDA approval for generic Ventolin HFA strengthens its respiratory portfolio and inhaler manufacturing strategy.
Pharma & Biotech
AbbVie’s fast-acting Botox rival just hit a regulatory wall, but not where investors feared
AbbVie’s TrenibotulinumtoxinE faces an FDA manufacturing CRL. Find out what this means for approval, aesthetics and neurotoxins.
Pharma & Biotech
Can China Medical University Hospital, Ever Supreme and SHINE OUT BIO reshape spinal cord injury repair?
New exosome therapy targets spinal cord injury repair non-invasively. Find out how this breakthrough could reshape neuroregenerative medicine.
Pharma & Biotech
Tivic Health Systems becomes Valion Bio but the real story lies in its biodefense pivot
Valion Bio’s pivot to biodefense and oncology could reshape biotech funding. Find out what this transformation means for investors and the industry.